Pancreatic cancer: Advances and challenges

CJ Halbrook, CA Lyssiotis, MP di Magliano, A Maitra - Cell, 2023 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Tumor microenvironment in pancreatic cancer pathogenesis and therapeutic resistance

MH Sherman, GL Beatty - Annual Review of Pathology …, 2023 - annualreviews.org
Pancreatic ductal adenocarcinoma (PDAC) features a prominent stromal microenvironment
with remarkable cellular and spatial heterogeneity that meaningfully impacts disease …

Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment

D Barkley, R Moncada, M Pour, DA Liberman, I Dryg… - Nature …, 2022 - nature.com
Transcriptional heterogeneity among malignant cells of a tumor has been studied in
individual cancer types and shown to be organized into cancer cell states; however, it …

Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment

WL Hwang, KA Jagadeesh, JA Guo, HI Hoffman… - Nature …, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal and treatment-refractory
cancer. Molecular stratification in pancreatic cancer remains rudimentary and does not yet …

Translational advances in pancreatic ductal adenocarcinoma therapy

AN Hosein, SK Dougan, AJ Aguirre, A Maitra - Nature cancer, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is most frequently
detected at advanced stages, limiting treatment options to systemic chemotherapy with …

Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment

LD Wood, MI Canto, EM Jaffee, DM Simeone - Gastroenterology, 2022 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

[HTML][HTML] Proteogenomic characterization of pancreatic ductal adenocarcinoma

L Cao, C Huang, DC Zhou, Y Hu, TM Lih, SR Savage… - Cell, 2021 - cell.com
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data

AA Connor, S Gallinger - Nature Reviews Cancer, 2022 - nature.com
Pancreatic ductal adenocarcinoma (PDAC), already among the deadliest epithelial
malignancies, is rising in both incidence and contribution to overall cancer deaths. Decades …

Pancreatic cancer

JD Mizrahi, R Surana, JW Valle, RT Shroff - The Lancet, 2020 - thelancet.com
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10%
in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk …

Applications of single-cell sequencing in cancer research: progress and perspectives

Y Lei, R Tang, J Xu, W Wang, B Zhang, J Liu… - Journal of hematology & …, 2021 - Springer
Single-cell sequencing, including genomics, transcriptomics, epigenomics, proteomics and
metabolomics sequencing, is a powerful tool to decipher the cellular and molecular …